GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
发明人:
HUIPING AMY GUAN,MICHAEL P. DEMARTINO
申请号：
BR112017004900
公开号：
BR112017004900A2
申请日:
2015.09.09
申请国别(地区):
BR
年份:
2017
代理人:
摘要：
pyridone derivatives as rearranged kinase inhibitors during transfection (ret) This invention relates to novel compounds which are rearranged kinase inhibitors during transfection (ret), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of tenderness, motility and / or gastrointestinal discharge and / or abdominal diseases or disorders and / or treatment related to disorders of ret dysfunction or where modulation of ret activity may have therapeutic benefit including, without limitation, all classifications of irritable bowel syndrome (ibs) including predominant diarrhea, predominant constipation or alternating stool pattern, functional swelling, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, esophageal disorders functional, gastroduodenal disorders functional diseases, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, thyroid medullary cancer, thyroid follicular cancer, anaplastic thyroid cancer, papillary thyroid cancer, tumors brain, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, von hippel-lindau syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer , transitional cell cancer, prostate cancer, esophageal cancer and gastroesophageal junction, biliary cancer, adenocarcinoma and any malignancy with ret major kinase activity.resumo ?derivados de piridona como inibidores de quinase rearranjada durante transfecção (ret)? esta invenção se refere a compostos inovadores que são inibidores da quinase rearranjada durante transfecção (ret), para as composições farmacêuticas que contêm as mesmas, para processos para sua preparação, e para seu uso em terapia, sozinhos ou
